Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2024-03-18 00:00:00 ET · period of report 2024-03-15 · accession 0001610717-24-000166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-18 | 2024-03-15 | ANTX | Chanda Sanjay | Chief Development Off | A - Grant | $0.00 | +27.5K | 28.2K | +3,741% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | Chanda Sanjay | Chief Development Off | A - Grant | $0.00 | +55.0K | 55.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-15 | A | A | 27,500 | $0.00 | 28,235 | D | — | — | (F1) These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. (F2) Reflects the adjusted total which includes the purchase of 735 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on September 29, 2023. |
| 2 | Derivative | Stock Option (right to buy) | 2024-03-15 | A | A | 55,000 | $0.00 | 55,000 | D | $3.00 · — to 2034-03-14 | 55,000 Common Stock | (F3) The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. |